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Abstract 
Background: Health claims regarding the cholesterol-lowering effect of soluble fiber from oat products, 
approved by food standards agencies worldwide, are based on a diet containing ≥3 g/d of oat β-glucan 
(OBG). Given the number of recently published randomized controlled trials (RCTs), it is important to 
update the findings of previous meta-analyses. Objective: The objective was to quantify the effect of ≥3 g 
OBG/d on serum cholesterol concentrations in humans and investigate potential effect modifiers. Design: 
A meta-analysis was performed on 28 RCTs comparing ≥3 g OBG/d with an appropriate control. 
Systematic searches were undertaken in PubMed, AGRICOLA, and Scopus between 1 January 1966 and 6 
June 2013, plus in-house study reports at CreaNutrition AG. Studies were assessed with regard to 
inclusion/exclusion criteria, and data were extracted from included studies by reviewers working 
independently in pairs, reconciling differences by consensus. Estimates of the mean reduction in serum 
cholesterol from baseline between the OBG and control diets were analyzed by using random-effects 
meta-analysis models and meta-regression. Results: OBG in doses of ≥3 g/d reduced low-density 
lipoprotein (LDL) and total cholesterol relative to control by 0.25 mmol/L (95% CI: 0.20, 0.30; P < 0.0001) 
and 0.30 mmol/L (95% CI: 0.24, 0.35; P < 0.0001), respectively, with some indication of heterogeneity (P = 
0.13 and P = 0.067). There was no significant effect of OBG on high-density lipoprotein (HDL) cholesterol 
or triglycerides and no evidence that dose (range across trials: 3.0–12.4 g/d) or duration of treatment 
(range: 2–12 wk) influenced the results. LDL cholesterol lowering was significantly greater with higher 
baseline LDL cholesterol. There was a significantly greater effect for both LDL and total cholesterol in 
subjects with diabetes compared with those without (although based on few studies). Conclusions: 
Adding ≥3 g OBG/d to the diet reduces LDL and total cholesterol by 0.25 mmol/L and 0.30 mmol/L, 
respectively, without changing HDL cholesterol or triglycerides. 
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Original Research Communications
Cholesterol-lowering effects of oat b-glucan: a meta-analysis of
randomized controlled trials1–4
Anne Whitehead, Eleanor J Beck, Susan Tosh, and Thomas MS Wolever
ABSTRACT
Background: Health claims regarding the cholesterol-lowering ef-
fect of soluble fiber from oat products, approved by food standards
agencies worldwide, are based on a diet containing $3 g/d of oat
b-glucan (OBG). Given the number of recently published random-
ized controlled trials (RCTs), it is important to update the findings
of previous meta-analyses.
Objective: The objective was to quantify the effect of$3 g OBG/d on
serum cholesterol concentrations in humans and investigate potential
effect modifiers.
Design: A meta-analysis was performed on 28 RCTs comparing
$3 g OBG/d with an appropriate control. Systematic searches were
undertaken in PubMed, AGRICOLA, and Scopus between 1 January
1966 and 6 June 2013, plus in-house study reports at CreaNutrition
AG. Studies were assessed with regard to inclusion/exclusion criteria,
and data were extracted from included studies by reviewers working
independently in pairs, reconciling differences by consensus. Estimates
of the mean reduction in serum cholesterol from baseline between
the OBG and control diets were analyzed by using random-effects
meta-analysis models and meta-regression.
Results: OBG in doses of $3 g/d reduced low-density lipoprotein
(LDL) and total cholesterol relative to control by 0.25 mmol/L (95%
CI: 0.20, 0.30; P, 0.0001) and 0.30 mmol/L (95% CI: 0.24, 0.35; P,
0.0001), respectively, with some indication of heterogeneity (P = 0.13
and P = 0.067). There was no significant effect of OBG on high-density
lipoprotein (HDL) cholesterol or triglycerides and no evidence that dose
(range across trials: 3.0–12.4 g/d) or duration of treatment (range: 2–12
wk) influenced the results. LDL cholesterol lowering was significantly
greater with higher baseline LDL cholesterol. There was a significantly
greater effect for both LDL and total cholesterol in subjects with diabetes
compared with those without (although based on few studies).
Conclusions: Adding $3 g OBG/d to the diet reduces LDL and
total cholesterol by 0.25 mmol/L and 0.30 mmol/L, respectively,
without changing HDL cholesterol or triglycerides. Am J Clin Nutr
2014;100:1413–21.
Keywords b-glucan, HDL cholesterol, LDL cholesterol, total
cholesterol, triglyceride, meta-analysis, oats
INTRODUCTION
European guidelines for the management of dyslipidemias (1) note
the strong evidence supporting a relation between total and LDL
cholesterol lowering and reduced cardiovascular disease risk and rec-
ommend that lifestyle modifications, such as consuming 5–15 g/d sol-
uble fiber from oat products, may be beneficial. U.S. guidelines (2)
recommend a multifaceted lifestyle approach, including dietary options
for LDL cholesterol lowering, such as consuming 10–25 g/d soluble
fiber from oat products and other foods.
Oat b-glucan (OBG)5, the main soluble fiber found in oats, is seen
as the main active component responsible for their cholesterol-lowering
effect. Health claims regarding the association between cholesterol
lowering and soluble fiber from oat products/OBG have been approved
by food standards agencies worldwide [United States: U.S. Food and
Drug Administration (3); Canada: Health Canada (4); Europe: Euro-
pean Food Safety Authority (5); Australia and New Zealand: Food
Standards Australia New Zealand (6); Malaysia: Ministry of Health
Malaysia (7)]. Except for Malaysia, these approvals are based on a diet
containing at least 3 g OBG/d, although specific conditions may vary;
for example, the Food and Drug Administration (3) allows individual
servings, including 0.75 g OBG, whereas the European Food Safety
Authority (8) requires 1-g portions.
A meta-analysis of 12 randomized controlled trials (RCTs)
published between 1985 and 1991 showed that oat products
reduced total cholesterol by 0.13 mmol/L, with a higher intake of
soluble fiber ($3 compared with ,3 g/d) having a significantly
1 From the Medical & Pharmaceutical Statistics Research Unit, Department
of Mathematics and Statistics, Lancaster University, Lancaster, United King-
dom (AW); the School of Medicine and Illawarra Health and Medical Re-
search Institute, University of Wollongong, Wollongong, Australia (EJB);
Agriculture and Agri-Food Canada, Guelph, Canada (ST); and the Department
of Nutritional Sciences, University of Toronto, Toronto, Canada (TMSW).
2 Supportedby DSM Nutritional Products. This is a free access article,
distributed under terms (http://www.nutrition.org/publications/guidelines-
and-policies/license/) that permit unrestricted noncommercial use, distribution,
and reproduction in any medium, provided the original work is properly cited.
3 SupplementalTables 1–4, Supplemental Figure 1, and Supplemental Methods
are available from the “Supplemental data” link in the online posting of the article
and from the same link in the online table of contents at http://ajcn.nutrition.org.
4 Address correspondence to A Whitehead, Medical & Pharmaceutical
Statistics Research Unit, Department of Mathematics and Statistics, Fylde
College, Lancaster University, Lancaster LA1 4YF, United Kingdom.
E-mail: p.a.whitehead@lancaster.ac.uk.
5 Abbreviations used: MW, molecular weight; OBG, oat b-glucan; RCT,
randomized controlled trial.
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Supplemental Material can be found at:
greater effect (9). A meta-analysis of 25 RCTs published
between 1966 and 1996 showed that oat products reduced total
and LDL cholesterol, respectively, by 0.040 and 0.037 mmol/L
per gram of daily soluble fiber intake (10). Kelly et al. (11) included
8 RCTs published between 1991 and 2005 in a meta-analysis
showing that oat products reduced total and LDL cholesterol,
respectively, by 0.19 and 0.18 mmol/L.
However, an updated meta-analysis is timely and important for
several reasons. The previous meta-analyses included studies
with intakes of oat soluble fiber,3 g/d; thus, their results do not
provide an accurate estimate of the effect on serum cholesterol
of complying with the food standards agencies’ requirement that
cholesterol-lowering claims for oats relate to daily intakes of$3 g
oat soluble fiber. Also, we found 10 studies including w1200
subjects published since 2005, which more than doubles the
amount of data now available for meta-analysis. Finally, previous
meta-analyses did not consider the molecular weight (MW) of
OBG, but this may be important because high MW may be nec-
essary to obtain a significant cholesterol-lowering effect. Therefore,
our primary objective was to quantify the effect of consuming
$3 g high-MW OBG/d on serum LDL, HDL, and total cho-
lesterol and triglyceride concentrations by using data from RCTs
comparing OBG with a control treatment.
METHODS
Literature search and study selection
Three electronic databases (PubMed, www.ncbi.nlm.nih.gov/
pubmed; AGRICOLA, agricola.nal.usda.gov; and Scopus, www.
elsevier.com/online-tools/scopus) were searched for relevant
published articles (papers and abstracts) between 1 January 1966
and 6 June 2013. The reference lists of articles found to be
relevant were checked for additional articles of relevance. The
in-house collection of study reports at CreaNutrition AG was
searched as well (CreaNutrition AG is the Switzerland-based
international marketing, sales, and research subsidiary of Swedish
Oat Fiber AB). The keywords used for the search were as follows:
1) (oat fibre OR oat fiber OR oat bran OR oat b-glucan OR oats
OR oat bran concentrate OR oatmeal) AND cholesterol and 2)
(oat fibre OR oat fiber OR oat bran OR oat b-glucan OR oats
OR oat bran concentrate OR oatmeal) AND serum lipids. Searches
were limited to human studies and publications in English.
An initial screening was undertaken for potentially relevant
studies by 2 reviewers (EJB and ST). Articles on studies testing
OBG as a dietary intervention for lipid lowering were retrieved
and allocated a unique paper identification number. All retrieved
studies were assessed with regard to inclusion and exclusion
criteria and study quality (Supplemental Tables 1 and 2). Trials
investigating the effect of $3 g OBG/d (MW $100 kDa) for
a minimum of 2 wk were to be included.
The increased intake of OBG could be achieved by consumption
of a range of food products such as bread, muesli, breakfast cereals,
cereal bars, biscuits, cereal drinks, muffins, and powders that
contained OBG in 1, 2, or more eating occasions during the day.
The control treatment could consist of a comparable food product
(bread, muesli, breakfast cereals, cereal bars, biscuits, cereal drinks,
muffins, or powders) without soluble fiber (i.e., low in fiber) or
a comparable food product high in insoluble fiber.We selected 2 wk
as the minimum intervention period in keeping with a previous
meta-analysis (10), because the cholesterol-lowering effect is not
immediate.
Because the MW of OBG influences its cholesterol-lowering
effect (12), we wanted to exclude studies with low MW OBG,
which would not be expected to have much effect at a dose of 3 g/d.
A MW of 100 kDa was chosen because this represents more than
95% degradation of native OBG (MW w2000 kDa), and below
100 kDa OBG displays Newtonian behavior (no entanglements)
and has a low viscosity at the relevant concentrations. Even though
3 g OBG/d with a MW of 210 kDa has been reported to have no
significant effect on LDL cholesterol, because there is no standard
procedure to extract and measure OBG MW, we wanted to err on
the side of including studies that may not have used high enough
MW rather than excluding those that did. However, studies did not
have to report MW to be included. Studies not reporting MW
could be included if one or more interventions were considered to
contain high MW OBG, based on our knowledge of the effects of
different food processing on b-glucan MW. Depolymerization is
usually observed during production of OBG concentrates and
extracts (13, 14). In general, the production of porridge, muesli,
biscuits, cereal bars, and muffins does not greatly affect MW
(15–17). Typical extrusion conditions are not severe enough to
cause much degradation of b-glucan (12, 16, 17), but high shear
can cause significant depolymerization (12).
The study populations included were generally healthy free-
living normocholesterolemic or hypercholesterolemic adult men
and women from the general population; subjects could be lean,
overweight, or obese and could have type 2 diabetes. The quality
criteria were based on Appendix H of the European Food Safety
Authority guidance for the preparation and presentation of the
application for authorization of a health claim (18). Assessors
worked in pairs independently to complete assessments for the
publications (EJB + ST, EJB + TMSW, ST + TMSW). They then
discussed their results and reconciled differences by consensus.
Data extraction and statistical analysis
Assessors worked in pairs to extract data from all included
studies into a data collection Excel spreadsheet (AW + EJB, ST,
and TMSW). They then discussed their results and reconciled
differences by consensus. The following information was ex-
tracted from each study whenever available: trial design (parallel
group, crossover); number of subjects randomized per treat-
ment arm; health status of study population (healthy, hyper-
lipidemic, diabetic); mean age; percentage of subjects who are
male; details of OBG treatment and control treatment; type of
control treatment (diet alone, cereal/low soluble fiber); daily dose
of OBG (g/d total); background diet (standard diet or advice
on weight maintenance, low fat/cholesterol lowering, energy
restriction); treatment duration (wk); mean baseline LDL and
total cholesterol (mmol/L); mean LDL, HDL, and total cholesterol
and triglyceride concentrations with standard deviations of
individual observations or standard errors of means, both at
baseline and after treatment and, if available, for change from
baseline for each treatment; and mean difference in the change
from baseline between the OBG and the control diets with
standard deviations of individual observations or standard errors
of means.
For trials comparing one dose of OBGwith a control treatment,
an estimate of the mean difference in cholesterol between OBG



























and control and its variance was calculated. The difference in the
change from baseline between OBG and control was calculated
where possible; otherwise, the difference in the mean cholesterol
between OBG and control at the end of the trial was used. For trials
comparing more than one dose of OBG with a control treatment,
estimates and variances were calculated for the differences between
each OBG dose and control. Covariance terms were included for
studies with more than one estimate of relative treatment effect (see
Supplemental Methods). Treatment arms in which the OBG dose
was ,3 g/d were excluded from the analysis.
Fixed- and random-effects meta-analyses were performed with
SAS Proc Mixed (version 9.2; SAS Institute) (19) by using ap-
proaches described by van Houwelingen et al. (20). The analyses
were based on the study estimates of the relative treatment effect
and their variances and covariances. We used x2 statistics to
test the null hypothesis of no treatment difference. Inferences
about the effect of OBG were made from the random-effects
meta-analyses. Heterogeneity between study estimates of relative
treatment effect was tested by using Cochran’s Q statistic (21)
and quantified by the I2 statistic (22), which measures the pro-
portion of between-trial variation in relative treatment effects
that is due to heterogeneity. The threshold for statistical sig-
nificance was P = 0.05.
Forest plots were used to display the relative treatment effect
and its 95% CI for each trial and dose amount and for the overall
fixed- and random-effects meta-analyses. In all plots, the area
of the circle at the estimate of the relative treatment effect is
proportional to the inverse variance of the estimate.
The effect of the following factors on the relative treatment
effect was investigated by fitting meta-regression models: trial
design, health status, mean age, percentage of subjects who were
male, type of control treatment, daily dose of OBG, background diet,
treatment duration, and mean baseline LDL and total cholesterol.
The statistical significance of the regression coefficients was tested
by using a x2 test.
The effect of the quality of the studies in relation to randomi-
zation, blinding, and reporting of subject compliance on the relative
treatment effects was also investigated by fitting meta-regressions.
Answers to 6 of the quality assessment questions (Q9a: Was
allocation to intervention random? Q9b:Was treatment allocation
concealed? Q11: Were subjects blinded to intervention received?
Q12: Were caregivers blinded to intervention given? Q13: Were
outcome assessors blinded to intervention given? Q14: Was com-
pliance of subjects with the intervention reported?) were used
to create 5 covariates. Answers to questions Q11–Q14 were
dichotomized as “yes” or anything else. A dichotomized score
based on both Q9a and Q9b was created with “yes” to both
questions or anything else. Funnel plots were presented to display
the relationship between the study estimates of mean treatment
difference and their precision for LDL and total cholesterol.
Estimates were shaded according to the number of “yes” answers
to the above 6 quality questions.
RESULTS
The initial screening yielded 355 publications. Based on titles
and abstracts, 97 were reviewed for inclusion in the meta-analysis
(Figure 1). Of these, 69 were excluded because they did not
meet the inclusion and exclusion criteria. Twelve studies were
excluded because the daily consumption of OBG was ,3 g/d.
These low-dose interventions had the potential to misrepresent
the magnitude of the effect of products carrying health claims
and the associated health benefit. Of the 97 studies reviewed,
information on MW was reported or found in related publications
for 14 studies reporting 20 comparisons (some articles included
several doses of OBG). Of these 20, 6 comparisons were excluded
on this basis. Available data for included studies are given in Table
1. Depolymerization is typically observed during production of
bread because of its susceptibility to enzymes during fermentation
(41). One study (44) used a combination of bread and muffins, and
another (32) used bread alone, but no MW data were provided, so
they were included.
The characteristics of the 27 published (12, 16, 17, 23–46) and
1 unpublished (Y. Donazzolo, M. Latreille-Barbier, C. Ruel, S.
Layre, R. Alken, M. Macmahon, unpublished results, 2006)
RCTs included in the meta-analysis are described in Table 1.
Eighteen RCTs had a parallel group design and 10 a crossover
design. The dose of OBG ranged from 3.0 to 12.4 g/d, and
FIGURE 1 Flow diagram. EC2: not sufficiently or appropriately con-
trolled: only baseline data provided and no control group during the treat-
ment period or an inappropriate control group (e.g., another soluble fiber).
EC4: any uncontrolled significant changes during the trial known to affect
blood lipid concentration—for example, a significant difference in total fat
or saturated fat intake between control and intervention groups, diets
contain other soluble fibers than soluble nonstarch polysaccharide from
oats, or uncontrolled significant body weight change (note: important only if
interventions are affected differently). EC7: insufficient information to estimate
the magnitude of the effect: no measure or estimate of soluble fiber or oat
b-glucan intake or limited amount of information on the outcome measures.
IC9: a formal assessment of diet and body weight changes during the trial. MW,
molecular weight; RCT, randomized controlled trial; TC, total cholesterol.









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































treatment duration ranged from 2 to 12 wk. Twelve studies re-
cruited healthy subjects, 13 recruited subjects with hypercho-
lesterolemia, and 3 recruited subjects with type 2 diabetes. The
study quality scores are provided in Supplemental Table 3.
The effect of OBG relative to control on LDL cholesterol for
all studies and dose amounts is shown in Figure 2A. There was
some indication of heterogeneity among the studies, although
this did not reach statistical significance (P = 0.13). The random-
effects analysis showed a statistically significant difference for
OBG relative to control of 20.25 mmol/L (95% CI: 20.30,
20.20; P , 0.0001). There was evidence of an increasing effect
with baseline LDL cholesterol (P = 0.039) and a significant, in-
creased effect for subjects with diabetes relative to healthy subjects
(P = 0.013) (Supplemental Table 4 and Supplemental Figure 1).
There was an indication of an increasing effect with baseline total
cholesterol (P = 0.074), age (P = 0.080), percentage of subjects
who were male (P = 0.054), and for hypercholesterolemic subjects
relative to healthy subjects (P = 0.079), although effects did not
reach statistical significance. No other factors showed a significant
effect.
The effect of OBG relative to control on total cholesterol for all
studies and dose amounts is shown in Figure 2B. There was some
indication of heterogeneity among the studies (P = 0.067). The
random-effects meta-analysis showed a statistically significant
difference for OBG relative to control of 20.30 mmol/L (95%
CI: 20.35, 20.24; P , 0.0001). There was a significantly
greater effect for subjects with type 2 diabetes relative to those
without diabetes (P = 0.004) (Supplemental Table 4). No other
factor showed a significant effect.
The effect of OBG relative to control on HDL cholesterol for
all studies and dose amounts is shown in Figure 3A. There was
significant evidence of heterogeneity among the studies (P, 0.001).
The random-effects meta-analysis of the effect of OBG relative to
control showed no significant difference (20.035 mmol/L; 95%
CI: 20.078, 0.008; P = 0.12). The results from the Beck et al.
(16) study are quite different from the rest. In a post hoc analysis
that omitted this study, there was little evidence of heterogeneity
(P = 0.18). Excluding the Beck et al. study, the random-effects
meta-analysis showed no significant difference between the
OBG and control treatments (20.007 mmol/L; 95% CI:20.025,
0.010; P = 0.41).
Because of the influence of the Beck et al. (16) study on the
HDL cholesterol results, the LDL and total cholesterol meta-
analyses were repeated without this study. Omitting the Beck et al.
study had little effect on the results for LDL and total cholesterol.
OBG tended to reduce serum triglyceride concentrations slightly
compared with control, but the difference was not significant
(20.023 mmol/L; 95% CI: 20.060, 0.015; P = 0.23) (Figure 3B).
There was little evidence of heterogeneity (P = 0.58).
To assess the effect of study quality on the results, we un-
dertook meta-regressions on each of the dichotomized quality
questions (Q11–Q14), as well as a composite of Q9a and Q9b,
for LDL and total cholesterol. These indicated a reduction in
the OBG effect between studies that met the quality criterion
FIGURE 2 Forest plots of estimates of mean differences (95% CIs). LDL cholesterol: heterogeneity (x2, P = 0.13; I2 = 22%) (A). TC: heterogeneity
(x2, P = 0.067; I2 = 28%) (B). The area of the circle is proportional to the inverse variance of the estimate of mean difference. For studies with more than one
OBG arm, the number of subjects randomized equals those randomly allocated to the particular OBG arm plus those to the control arm. For Beck et al. (16),
the 2 OBG doses were 5–6 and 8–9 g/d. For Davidson et al. (28), the 3 OBG doses were 84 g oatmeal (3.6 g/d), 56 g oat bran (4 g/d), and 84 g oat bran (6 g/d).
For Wolever et al. (12), the 4 OBG doses were 4 g/d low MW (4L), 3 g/d medium MW (3M), 4 g/d medium MW (4M), and 3 g/d high MW (3H). diff,
difference; MW, molecular weight; OBG, oat b-glucan; TC, total cholesterol; up, unpublished.



























compared with those that did not (Supplemental Table 4). How-
ever, these differences were not statistically significant apart from
Q13. The effect of OBG was significantly less by 0.11 mmol/L
(P = 0.024) on LDL cholesterol and 0.13 mmol/L (P = 0.021) on
total cholesterol for trials in which blinding of outcome assessors
was specifically mentioned relative to the other trials. Larger
effects of OBG on total cholesterol were associated with studies
of a lower precision (i.e., larger 95% CI), although this was less
obvious for LDL cholesterol (Figure 4).
DISCUSSION
We found that diets containing$3 g OBG/d reduce serum total
and LDL cholesterol relative to control by 0.30 and 0.25 mmol/L,
respectively, with no effect on HDL cholesterol or triglycerides.
Although generally confirming the results of previous meta-
analyses that oat products reduce serum cholesterol, the present
results differ in that the magnitude of the effects seen are 50–100%
greater than those reported in previous meta-analyses. This is
important because our study provides a more accurate assessment
of the effect on serum cholesterol of following the recommenda-
tions of food standards agencies to consume $3 g OBG/d than do
previous meta-analyses that included studies in which subjects
consumed,3 g OBG/d and studies in which OBG was more than
95% degraded.
We found no significant effect of dose or duration of treatment
of the range of OBG doses (3.0–12.4 g/d) and durations of
treatment (2–12 wk) used in the RCTs included in the meta-
analysis. The former suggests that a cholesterol-lowering effect
of oats can be achieved with the minimum dose (3 g/d) considered
effective by regulatory agencies and that consuming more may not
have any additional effect. The lack of dose response is curious
and somewhat unexpected because a significant effect of dose was
found in both previous meta-analyses that tested for it (9, 10).
However, the previous meta-analyses included studies with intakes
of OBG,3 g/d, and one (10) also assumed a linear dose-response
relation. Also, the ability of our meta-analysis to detect an effect of
dose may be limited because of unknown effects of unmeasured
confounding variables, such as the source of oats or the nature of
the food products used to deliver OBG, which may have affected
the physicochemical properties and, hence, viscosity of OBG (47).
It is believed that the cholesterol-lowering effect of OBG depends
on its viscosity in the small intestine, which, in turn, is affected by
the MWand amount of b-glucan in solution. The MWof b-glucan
may be reduced by b-glucanase before being incorporated into
food products by exposure to b-glucanase naturally present in
foods to which it is added (e.g., wheat flour) (41) or by heat and
pressure exerted on foods during processing. Viscosity is inversely
related to log (MW). Wolever et al. (12) showed a reduced
cholesterol-lowering effect of OBG with low MW (210 kDa)
relative to a medium MW (530 kDa) or high MW (2210 kDa).
We restricted our meta-analysis to studies including OBG with
MW $100 kDa. However, because there is no standardized
method for measuring the MWof b-glucan, this could have been
FIGURE 3 Forest plots of estimates of mean difference (95% CIs). HDL cholesterol: heterogeneity (x2, P , 0.001; I2 = 81%) (A). Triglycerides:
heterogeneity (x2, P = 0.58; I2 = 0%) (B). The area of the circle is proportional to the inverse variance of the estimate of mean difference. For studies with
more than one OBG arm, the number of subjects randomized equals those randomly allocated to the particular OBG arm plus those to the control arm. For
Beck et al. (16), the 2 OBG doses were 5–6 and 8–9 g/d. For Davidson et al. (28), the 3 OBG doses were 84 g oatmeal (3.6 g/d), 56 g oat bran (4 g/d), and 84 g
oat bran (6 g/d). For Wolever et al. (12), the 4 OBG doses were 4 g/d low MW (4L), 3 g/d medium MW (3M), 4 g/d medium MW (4M), and 3 g/d high MW
(3H). diff, difference; MW, molecular weight; OBG, oat b-glucan; up, unpublished.



























a source of confounding in our analysis. The amount of b-glucan
in solution in the small intestine depends on its ability to be solu-
bilized and released from the food matrix (i.e., bioaccessibility);
b-glucan solubility is known to be reduced by low water avail-
ability in a food and storage of hydrated b-glucan at cool tem-
peratures. Because we had no way of assessing the bioaccessibility
of the b-glucan in most studies included in our analysis, it also is
a potential source of confounding.
The lack of effect of study duration on the results suggests that
the effect of oats on serum cholesterol is durable, as found by
Bazzano et al. (48), but none of the studies we included lasted for
longer than 12 wk.
We found evidence that the LDL cholesterol-lowering effect of
oats was greater in subjects with type 2 diabetes and subjects with
higher baseline LDL cholesterol. Previous studies suggest that
the cholesterol-lowering effect of OBG is greater in nonwhites
than in whites (24, 31, 49); this, taken together with our results
suggesting that OBG has a greater effect in subjects with type 2
diabetes, might indicate that the OBG reduces serum cholesterol via
a mechanism or mechanisms related in some way to dysglycemia,
insulin resistance, and/or insulin secretion. Although type 2 dia-
betes generally is not associated with increased LDL cholesterol,
it is associated with increased secretion of VLDL particles, which,
after interaction with lipoprotein-lipase, hepatic-lipase, and
cholesterol-ester transfer protein, eventually are metabolized
to become LDL particles. In addition, this suggests that those with
increased risk for cardiovascular disease due to high cholesterol or
diabetes will obtain at least as much, if not more, benefit from the
cholesterol-lowering effect of oats as individuals without these risk
factors; however, these conclusions are based on a limited number
of studies and should be interpreted with caution.
The studies included a wide range of subjects, including
healthy individuals and those with hypercholesterolemia and
type 2 diabetes. The studies were conducted in Europe, North
America, Asia, and Australia. A wide range of common food
products were used to study the effect of b-glucan, including
rolled oats, whole oat flour, oat bran, bread, muffins, muesli,
breakfast cereals, cereal bars, and biscuits. Therefore, it would
appear that the results are applicable to the general population
and that benefits could be achieved eating regularly consumed
foods.
The funnel plots indicated that the studies with a lower pre-
cision had a tendency to show a more beneficial effect of OBG on
total cholesterol, although this effect was less obvious for LDL
cholesterol. This is sometimes taken to infer that there is pub-
lication bias—that is, a number of small studies have been un-
dertaken and not published because the effect is not statistically
significant or is negative. However, there may be other reasons,
such as larger studies being undertaken after promising results
from small studies. As suggested by the meta-regressions on the
quality questions, the funnel plots show some association between
OBG effect and study quality, with lower study quality being
associated with a larger effect. However, this might be explained
by study quality improving over time.
We conclude that there is robust evidence that consuming oats
or oat-containing food products containing at least 3 g OBG/d with
MW $100 kDa reduces serum cholesterol in lean, overweight,
or obese male and female adults without diabetes and those
with type 2 diabetes. Directions for future research include the
need for high-quality studies to determine whether there is
a dose-response effect of OBG and whether the effect persists in
the long term (i.e., longer than 3 mo). Because the purported
mechanisms of cholesterol lowering require a significant viscosity
of the gastrointestinal contents, and this is supported by recent
work (12, 41), future studies need to consider the physicochemical
properties of b-glucan in food products targeted at lowering
total and LDL cholesterol to ensure the intended physiologic
effects.
FIGURE 4 Funnel plots of inverse SE compared with the estimate of mean difference for LDL cholesterol (A) and TC (B). Shading of circles indicates
the number of 6 quality questions (Q9a, random sequence generation; Q9b, treatment allocation concealed randomization; Q11, blinding of subjects; Q12,
blinding of caregivers; Q13, blinding of outcome assessors; and Q14, reporting of subject compliance) with “yes”: empty, 0; lines, 1–3; hashed, 4–5; and solid,
6. The area of a circle is proportional to the inverse variance of estimate of mean difference. Q, question; TC, total cholesterol.
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lipids and postprandial glucose and insulin concentrations after consump-
tion of beverages with b-glucans from oats or barley: a randomised
dose-controlled trial. Eur J Clin Nutr 2005;59:1272–81.
14. Lazaridou A, Biliaderis CG, Micha-Screttas M, Steele BR. A comparative
study on structure-function relations of mixed-linkage (1/3), (1/4)
linear b-D-glucans. Food Hydrocoll 2004;18:837–55.
15. Aman P, Rimsten L, Andersson R. Molecular weight distribution of
b-glucan in oat-based foods. Cereal Chem 2004;81:356–60.
16. Beck EJ, Tapsell LC, Batterham MJ, Tosh SM, Huang XF. Oat beta-
glucan supplementation does not enhance the effectiveness of an energy-
restricted diet in overweight women. Br J Nutr 2010;103:1212–22.
17. Charlton KE, Tapsell LC, Batterham MJ, O’Shea J, Thorne R, Beck E,
Tosh SM. Effect of 6 weeks’ consumption of b-glucan-rich oat prod-
ucts on cholesterol levels in mildly hypercholesterolaemic overweight
adults. Br J Nutr 2012;107:1037–47.
18. European Food Safety Authority. Opinion of the panel on dietetic
products, nutrition and allergies (NDA) on a request from the commission
related to scientific and technical guidance for the preparation and
presentation of the application for authorisation of a health claim.
EFSA J 2007;5:530–574.
19. SAS Institute. The Mixed procedure. In: SAS/STAT 9.2 User’s Guide.
Cary (NC): SAS Institute; 2008.
20. van Houwelingen HC, Arends LR, Stijnen T. Tutorial in biostatistics:
advanced methods in meta-analysis: multivariate approach and meta-
regression. Stat Med 2002;21:589–624.
21. Cochran WG. The combination of estimates from different experi-
ments. Biometrics 1954;10:101–29.
22. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-
analysis. Stat Med 2002;21:1539–58.
23. Kabir M, Oppert JM, Vidal H, Bruzzo F, Fiquet C, Wursch P, Slama G,
Rizkalla SW. Four-week low-glycemic index breakfast with a modest amount
of soluble fibers in type 2 diabetic men. Metabolism 2002;51:819–26.
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